Racial Disparities in Diagnosis and Treatment of Patients With Dermatomyositis of Different Skin Tones

Abstract

Background Delays in the diagnosis and treatment of dermatological conditions in minorities are a well-documented health disparity. We aimed to determine if there was a delay in detection and treatment initiation for dermatomyositis (DM) and amyopathic dermatomyositis (ADM) in patients of different skin tones. Methods Patients from Montefiore Medical Center who met the criteria for DM and ADM were included in this cohort study. Records were reviewed for date of first documented rash, creatine kinase levels, muscle weakness complaints, and date of first steroid or disease-modifying antirheumatic drug initiation. The median number of days between rash documentation and therapy initiation was compared for patients of different races, including non-Hispanic White, non-Hispanic Black, Hispanic, and other (Asian and unknown). Data were compared in White versus non-White skin. Results Sixty-three DM and 9 ADM patients met the inclusion criteria. There was a shorter time to treatment initiation in White versus non-White patients, with a median number of 8 days compared with 21 days, respectively (p = 0.05). Kaplan-Meier curves showed prolonged time to diagnosis and treatment in all other races when compared with White patients (p = 0.03). Discussion It took clinicians longer to diagnose and treat DM and ADM in patients of color. The trends observed emphasize the importance of increasing dermatology education of non-White skin to improve detection and treatment of DM and ADM and minimize health disparities.

Refractory antimelanoma differentiation-associated gene 5 antibody negative ulcerative dermatomyositis responsive to mycophenolate mofetil

“…Furthermore, aspects such as race and ethnicity may have a potential impact on these clinical presentations, including the time it takes for symptoms to lead to diagnosis and subsequent treatment. 7 , 8 This points to the necessity for a deeper understanding of the varied clinical and immunologic characteristics of DM in diverse patient groups.…”